Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ACH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAccendra Health shareholders approve amended equity incentive plan at annual meeting
Filed May 15, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
medium
Shareholders approved the Amended and Restated 2023 Omnibus Incentive Plan with 97% support, allowing the Board's People & Culture Committee to grant stock awards to employees, directors, and consultants.
Item 5.02 verify on EDGAR → -
low
All six director nominees elected for one-year terms with 93-98% approval; Edward Pesicka received lowest support at 93% while other directors received 97-98%.
Item 5.07 verify on EDGAR → -
low
Say-on-pay vote passed with 92% support, indicating general shareholder approval of executive compensation though support was lower than other proposals.
Item 5.07 verify on EDGAR → -
low
KPMG LLP ratified as independent auditor for fiscal 2026 with 99% approval, maintaining continuity in external audit relationship.
Item 5.07 verify on EDGAR →
Summary
Accendra Health held its 2026 Annual Meeting on May 14, where shareholders voted on routine governance matters. The most significant action was approval of the amended equity incentive plan, which updates the company's 2023 plan and authorizes the Board's People & Culture Committee to grant stock-based compensation to employees, directors, and consultants.
This passed with strong 97% support, giving management flexibility to use equity as a retention and recruitment tool. All director elections and other proposals passed comfortably. The say-on-pay vote received 92% approval—lower than other items but still indicating general satisfaction with executive compensation practices. With 81% shareholder participation, the meeting had strong quorum.
Retail investors should watch for details on equity grant activity under the amended plan in future proxy statements, as increased dilution from stock awards could impact per-share value. The plan's specific terms and any material changes from the prior version were detailed in the April 2, 2026 proxy statement.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 14, 2026 at the 2026 Annual Meeting of Shareholders (the “Annual Meeting”) of Accendra Health, Inc. (the “Company”), the shareholders approved the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan (the “Amended and Restated 2023 Plan”) which amends and restates the Owens & Minor, Inc. 2023 Omnibus Incentive Plan (as amended as of March 14, 2024).
Shareholders approved an amended equity incentive plan at the annual meeting. The plan updates the existing 2023 Omnibus Incentive Plan that was previously amended in March 2024. Details of the amendments are referenced in the April 2, 2026 proxy statement.
Added in current filing · verify on EDGAR →
Under the terms of the Amended and Restated 2023 Plan, the Board of Directors (the “Board”) has authorized the Our People & Culture Committee of the Board to grant equity and other incentive awards to employees, non-employee directors and consultants.
The Board delegated authority to the People & Culture Committee to grant equity and incentive awards under the amended plan. Awards can be granted to employees, non-employee directors, and consultants, with each grant documented by individual agreements.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Accendra Health held its 2026 Annual Meeting, electing six directors and approving auditor ratification, executive compensation, and equity plan.
Added in current filing · verify on EDGAR →
Approval of the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan as follows: Votes | Votes For | Votes Against | Abstentions | Broker | Non-Votes | 50,645,557 | 1,573,141 | 151,765 | 9,763,670
Shareholders approved amendments to the company's 2023 equity incentive plan with approximately 97% support. This plan governs stock-based compensation for employees and executives, and the approval allows the company to continue granting equity awards under updated terms.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 28, 2026 · How we verify